Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma

Abstract Treatment effectiveness in hepatocellular carcinoma (HCC) depends on early detection and precision-medicine-based patient stratification for targeted therapies. However, the lack of robust biomarkers, particularly a non-invasive diagnostic tool, precludes significant improvement of clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yotsawat Pomyen, Anuradha Budhu, Jittiporn Chaisaingmongkol, Marshonna Forgues, Hien Dang, Mathuros Ruchirawat, Chulabhorn Mahidol, Xin Wei Wang, the TIGER-LC Consortium
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cbb7317501a94057b24fadd595fff2ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cbb7317501a94057b24fadd595fff2ab
record_format	dspace
spelling	oai:doaj.org-article:cbb7317501a94057b24fadd595fff2ab2021-12-02T14:59:29ZTumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma10.1038/s41598-021-91560-12045-2322https://doaj.org/article/cbb7317501a94057b24fadd595fff2ab2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91560-1https://doaj.org/toc/2045-2322Abstract Treatment effectiveness in hepatocellular carcinoma (HCC) depends on early detection and precision-medicine-based patient stratification for targeted therapies. However, the lack of robust biomarkers, particularly a non-invasive diagnostic tool, precludes significant improvement of clinical outcomes for HCC patients. Serum metabolites are one of the best non-invasive means for determining patient prognosis, as they are stable end-products of biochemical processes in human body. In this study, we aimed to identify prognostic serum metabolites in HCC. To determine serum metabolites that were relevant and representative of the tissue status, we performed a two-step correlation analysis to first determine associations between metabolic genes and tissue metabolites, and second, between tissue metabolites and serum metabolites among 49 HCC patients, which were then validated in 408 additional Asian HCC patients with mixed etiologies. We found that certain metabolic genes, tissue metabolites and serum metabolites can independently stratify HCC patients into prognostic subgroups, which are consistent across these different data types and our previous findings. The metabolic subtypes are associated with β-oxidation process in fatty acid metabolism, where patients with worse survival outcome have dysregulated fatty acid metabolism. These serum metabolites may be used as non-invasive biomarkers to define prognostic tumor molecular subtypes for HCC.Yotsawat PomyenAnuradha BudhuJittiporn ChaisaingmongkolMarshonna ForguesHien DangMathuros RuchirawatChulabhorn MahidolXin Wei Wangthe TIGER-LC ConsortiumNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yotsawat Pomyen Anuradha Budhu Jittiporn Chaisaingmongkol Marshonna Forgues Hien Dang Mathuros Ruchirawat Chulabhorn Mahidol Xin Wei Wang the TIGER-LC Consortium Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma
description	Abstract Treatment effectiveness in hepatocellular carcinoma (HCC) depends on early detection and precision-medicine-based patient stratification for targeted therapies. However, the lack of robust biomarkers, particularly a non-invasive diagnostic tool, precludes significant improvement of clinical outcomes for HCC patients. Serum metabolites are one of the best non-invasive means for determining patient prognosis, as they are stable end-products of biochemical processes in human body. In this study, we aimed to identify prognostic serum metabolites in HCC. To determine serum metabolites that were relevant and representative of the tissue status, we performed a two-step correlation analysis to first determine associations between metabolic genes and tissue metabolites, and second, between tissue metabolites and serum metabolites among 49 HCC patients, which were then validated in 408 additional Asian HCC patients with mixed etiologies. We found that certain metabolic genes, tissue metabolites and serum metabolites can independently stratify HCC patients into prognostic subgroups, which are consistent across these different data types and our previous findings. The metabolic subtypes are associated with β-oxidation process in fatty acid metabolism, where patients with worse survival outcome have dysregulated fatty acid metabolism. These serum metabolites may be used as non-invasive biomarkers to define prognostic tumor molecular subtypes for HCC.
format	article
author	Yotsawat Pomyen Anuradha Budhu Jittiporn Chaisaingmongkol Marshonna Forgues Hien Dang Mathuros Ruchirawat Chulabhorn Mahidol Xin Wei Wang the TIGER-LC Consortium
author_facet	Yotsawat Pomyen Anuradha Budhu Jittiporn Chaisaingmongkol Marshonna Forgues Hien Dang Mathuros Ruchirawat Chulabhorn Mahidol Xin Wei Wang the TIGER-LC Consortium
author_sort	Yotsawat Pomyen
title	Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma
title_short	Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma
title_full	Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma
title_fullStr	Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma
title_full_unstemmed	Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma
title_sort	tumor metabolism and associated serum metabolites define prognostic subtypes of asian hepatocellular carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/cbb7317501a94057b24fadd595fff2ab
work_keys_str_mv	AT yotsawatpomyen tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma AT anuradhabudhu tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma AT jittipornchaisaingmongkol tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma AT marshonnaforgues tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma AT hiendang tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma AT mathurosruchirawat tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma AT chulabhornmahidol tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma AT xinweiwang tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma AT thetigerlcconsortium tumormetabolismandassociatedserummetabolitesdefineprognosticsubtypesofasianhepatocellularcarcinoma
_version_	1718389229233373184

Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma

Ejemplares similares